Drug Type Drug conjugates |
Synonyms |
Target |
Mechanism CD14 inhibitors(Monocyte differentiation antigen CD14 inhibitors), MAdCAM-1 inhibitors(Mucosal addressin cell adhesion molecule-1 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sepsis | Preclinical | US | 19 Jan 2024 | |
Crohn Disease | Preclinical | US | - | |
Psoriasis | Preclinical | US | - | |
Rheumatoid Arthritis | Preclinical | US | - |